Navigation Links
Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
Date:4/1/2008

osition of clinical trials, the report reveals that only 25 percent of those taking part in cancer studies in 2003 were over 65 years of age. Older Americans are also routinely left out of clinical trials studying diseases associated with aging, such as Alzheimer's disease, arthritis, and incontinence.

At the same time, the report finds that the biomedical research community has been unsuccessful in resolving the under-representation of women, older adults, and racial and ethnic minorities in clinical research studies, despite many efforts to improve the performance in this area. One study cited in the report that examined the composition of clinical trials testing new cancer drugs between 1995-1999 found less than 10 percent of the patients studied collectively represented African Americans, Asian/Pacific Islanders, Hispanics and Native Americans.

"Although disparities in clinical trials has been discussed and debated extensively, this problem has generally been under-addressed and, as a result, has received little direct, systematic, or sustained intervention," said Armin D. Weinberg, Ph.D., Director of Baylor College of Medicine's Chronic Disease Prevention and Control Research Center and EDICT's Principal Investigator. "This report is intended as a nationwide call to action and is provided as a blueprint for removing the barriers to clinical trial participation, which is a critical step to improving the health status of all Americans."

More than an issue of fairness, the EDICT report associates better designed clinical research studies with the increased ability of scientists to catalog and understand the influence of genetic and non-genetic factors on individual and group responses to treatments, now possible as a result of the successful sequencing of the human genome. Findings from the large amount of genetic data generated to date show that more than 90 percent of the observed genetic variations occur within rather than between gro
'/>"/>

SOURCE Eliminating Disparities in Clinical Trials
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. Cancer Cure Coalition Proposes Major Changes at the FDA
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
5. Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression
6. Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo
7. Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
8. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
9. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... of the most important organs in the human body. ... food properly this is its synthesis function ... this is its detoxification function. Lack of exercise ... damage the liver. The resulting diseased cells can lead ... liver failure. According to the German Liver Foundation, over ...
(Date:7/9/2014)... 2014 A study published in the scientific journal ... Robert Bonin, two researchers at Universit Laval, reveals that ... new method that involves rekindling pain so that it ... novel means to alleviate chronic pain. , The researchers ... Institut universitaire en sant mentale de Qubec (IUSMQ) were ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... , MILFORD, Mass., Sept. 1 ... the Analytical Chemistry Division of the American Chemical Society presented ... Findeis Award for Achievements by a Young Analytical Scientist. Through ... Engen has pioneered the combined use of hydrogen-deuterium ...
... SAN ANTONIO, Sept. 1 Mission Pharmacal ... a one-of-a-kind formulation that provides fast, effective relief from the ... Esrubar, L.P., and formerly distributed by Beta Dermaceuticals, Inc. ... Mission Pharmacal,s strategy to accelerate growth by continuing to expand ...
... , PLANO, Texas, Sept. 1 American Institute for ... metro-Dallas area, is using Artefill to help patients fight wrinkles for ... only FDA-approved microsphere-enhanced collagen filler for the correction of smile lines ... Raphael and Dr. Scott Harris have been using to treat patients ...
... , , SCHAUMBURG, Ill., Sept. 1 ... Veterinary Medical Association (AVMA) reveal an economic mixed bag when it ... , The survey results appear in the Journal ... 2009, article entitled, "Employment, starting salaries, and educational indebtedness of year-2009 ...
... , SAN DIEGO, Sept. 1 Volcano Corporation (Nasdaq: ... products for the diagnosis and treatment of coronary and peripheral artery disease, ... Healthcare Conference 2009 on Wednesday, September 9. , , ... a.m., Eastern Daylight Time (5 a.m., Pacific Daylight Time). , , ...
... , , , ... showed that in patients treated with LIVALO (pitavastatin), high-density ... patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results ... have comparable efficacy to atorvastatin and simvastatin, as measured ...
Cached Medicine News:Health News:American Chemical Society Awards John R. Engen for Scientific Achievements 2Health News:American Chemical Society Awards John R. Engen for Scientific Achievements 3Health News:Mission Pharmacal Acquires Dr. Smith's Diaper Ointment 2Health News:American Institute for Plastic Surgery is Using Artefill to Fight Patient Wrinkles 2Health News:American Institute for Plastic Surgery is Using Artefill to Fight Patient Wrinkles 3Health News:AVMA Survey Indicates Most Starting Salaries Are Up for New Veterinarians 2Health News:AVMA Survey Indicates Most Starting Salaries Are Up for New Veterinarians 3Health News:Volcano Corporation Presentation at Weisel Conference to be Webcast 2Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 2Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 3Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 4Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 5
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
Medicine Products: